Junming Yie

Immunology and Microbiology · Life Sciences

20h-index3.9kcitations28works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

interferon and immune responses(8), RNA Research and Splicing(7), Fibroblast Growth Factor Research(6), Epigenetics and DNA Methylation(5), Kruppel-like factors research(5)

Publications28 total

Current state and challenges in respiratory syncytial virus drug discovery and development
Antiviral Research·2023· 20 cited
A protective human antibody against respiratory syncytial virus by targeting a prefusion epitope across sites IV and V of the viral fusion glycoprotein
hLife·2023· 13 citedOpen Access
Development of a robust functional cell-based assay for replacing the rabbit blood sugar bioidentity test of insulin glargine drug substance
Journal of Pharmaceutical and Biomedical Analysis·2020· 6 cited
Molecular mechanism of an antagonistic antibody against glucose-dependent insulinotropic polypeptide receptor
mAbs·2020· 8 citedOpen Access
Anti-obesity effects of GIPR antagonists alone and in combination with GLP-1R agonists in preclinical models
Science Translational Medicine·2018· 217 citedOpen Access
Erratum: Non-homeostatic body weight regulation through a brainstem-restricted receptor for GDF15
Nature·2017· 10 citedOpen Access
Non-homeostatic body weight regulation through a brainstem-restricted receptor for GDF15
Nature·2017· 590 cited
PROCÉDÉ DE TRAITEMENT OU D'AMÉLIORATION DE TROUBLES MÉTABOLIQUES À L'AIDE DE PROTÉINES DE LIAISON AU RÉCEPTEUR DU PEPTIDE INHIBITEUR GASTRIQUE (GIPR) EN ASSOCIATION AVEC DES AGONISTES DU GLP-1
2017
A Novel Fc-FGF21 With Improved Resistance to Proteolysis, Increased Affinity Toward β-Klotho, and Enhanced Efficacy in Mice and Cynomolgus Monkeys
Endocrinology·2017· 103 citedOpen Access
Monoclonal Antibodies for Musculoskeletal, CNS, and Other Diseases
2016
Polyethylene Glycol Modified FGF21 Engineered to Maximize Potency and Minimize Vacuole Formation
Bioconjugate Chemistry·2013· 61 cited
A Novel Approach to Improve the Function of FGF21
BioDrugs·2013· 20 cited
Rationale-Based Engineering of a Potent Long-Acting FGF21 Analog for the Treatment of Type 2 Diabetes
PLoS ONE·2012· 163 citedOpen Access
Understanding the Physical Interactions in the FGF21/FGFR/β‐Klotho Complex: Structural Requirements and Implications in FGF21 Signaling
Chemical Biology & Drug Design·2012· 95 citedOpen Access
FGF21 N‐ and C‐termini play different roles in receptor interaction and activation
FEBS Letters·2008· 149 cited
Pharmacological characterization of a small molecule inhibitor of c-Jun kinase
American Journal of Physiology-Endocrinology and Metabolism·2008· 23 cited
Genetic Analysis of Adipogenesis through Peroxisome Proliferator-activated Receptor γ Isoforms
Journal of Biological Chemistry·2002· 243 citedOpen Access
Ordered Recruitment of Chromatin Modifying and General Transcription Factors to the IFN-β Promoter
Cell·2000· 730 citedOpen Access
Gene Repression by Coactivator Repulsion
Molecular Cell·2000· 72 citedOpen Access
Mechanism by which the IFN-β enhanceosome activates transcription
Proceedings of the National Academy of Sciences·1999· 117 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

Dimitris Thanos(10), Murielle M. Véniant(6), Carlos Escalante(4), Menie Merika(4), Kate Senger(4), Liying Deng(4), Randy Hecht(4), Ed Belouski(4), Shanaka Stanislaus(4), Jing Xu(4), Theodora Agalioti(3), Aneel K. Aggarwal(3), Jinghong Wang(3), D.L. Bates(3), Xiaoshan Min(3), Todd Hager(3), Zhulun Wang(3), David J. Lloyd(3), Yuesheng Li(3), Wei Wang(3)